Specific TLR4 antagonists for the treatment of multiple myeloma

摘要

The invention relates to a specific TLR4 antagonist ("toll like receptor 4") for the treatment of multiple myeloma in patients with multiple myeloma, and an anti-tumor drug combination comprising () TLR4 specific antagonist and () II chemotherapy agent. It is used to treat multiple myeloma simultaneously, separately or sequentially.